Complement C3 is a novel plasma clot component with anti-fibrinolytic properties

Diab Vasc Dis Res. 2012 Jul;9(3):216-25. doi: 10.1177/1479164111432788. Epub 2012 Jan 17.

Abstract

Background and method: Increased plasma clot density and prolonged lysis times are associated with cardiovascular disease. In this study, we employed a functional proteomics approach to identify novel clot components which may influence clot phenotypes.

Results: Analysis of perfused, solubilised plasma clots identified inflammatory proteins, including complement C3, as novel clot components. Analysis of paired plasma and serum samples confirmed concentration-dependent incorporation of C3 into clots. Surface plasmon resonance indicated high-affinity binding interactions between C3 and fibrinogen and fibrin. Turbidimetric clotting and lysis assays indicated C3 impaired fibrinolysis in a concentration-dependent manner, both in vitro and ex vivo.

Conclusion: These data indicate functional interactions between complement C3 and fibrin leading to prolonged fibrinolysis. These interactions are physiologically relevant in the context of protection following injury and suggest a mechanistic link between increased plasma C3 concentration and acute cardiovascular thrombotic events.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Complement C3 / metabolism*
  • Complement Factor H / metabolism
  • Female
  • Fibrin / metabolism*
  • Fibrinogen / metabolism*
  • Fibrinolysis / physiology*
  • Humans
  • Male
  • Plasma / metabolism
  • Thrombosis / metabolism*

Substances

  • Complement C3
  • Complement Factor H
  • Fibrin
  • Fibrinogen